NATIONAL-TSING
12.5.2020 11:02:12 CEST | Business Wire | Press release
On May 9 National Tsing Hua University entered into an agreement to jointly establish the Taipei School of Economics and Political Science (TSE) together with the TSE Foundation, which was set up with a US$100 million donation from entrepreneur Lin Chen-hai, the founder of the Pau Jar Group. The mission of the TSE will be to provide world-class education in economics, international politics, and public affairs, with Asia as the center of gravity, and will soon begin recruiting top-notch faculty from around the world.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200512005343/en/
At the signing ceremony, TSE Foundation chairman Huang Huang-hsiung said that the TSE will be located on the NTHU campus, and that this type of cooperation between the public and private sectors is a new first in the history of higher education in Taiwan.
Also present at the ceremony was Minister of Education Pan Wen-chung, who said that the establishment of the TSE is undoubtedly a new milestone for higher education in Taiwan. NTHU president Hocheng Hong said that the plan for establishing the TSE has already been approved by the Ministry of Education, and that it will soon begin recruiting master’s and doctoral students for the 2021-22 school year, two thirds of whom will be international students, adding that all courses will be taught in English.
Chairman Huang said that the TSE aims to attract outstanding students and world-class faculty, for which purpose he is helping to set up an international advisory committee, which includes four former ministers of education to arrange academic exchanges with such well-known institutions as the London School of Economics(LSE) and the Harvard Kennedy School.
NTHU president Hocheng Hong said that public-private cooperation in education on such a scale is unprecedented, pointing out that Lin’s US$100 million donation is the largest ever made in the field of social science education in Taiwan.
Hocheng asserted that technology is a major factor in all of the most pressing challenges facing humanity, such as food security, environmental preservation, energy, war, and even epidemics, and that any viable solution must take account of technological, political, and economic factors, adding that this was one of the principle motivations for establishing the TSE at National Tsing Hua University.
Hocheng said that the TSE will be the eleventh college at NTHU, and that its multi-disciplinary master’s and doctoral programs will be modeled on those of the LSE. The TSE plans to admit at least ten master’s students for the 2021-22 school year, and in the following school year at least 40 master’s students and ten doctoral students, after which enrollment numbers will gradually increase year by year. During the initial phase, TSE classes will be held in the Innovation Incubation Building on the NTHU campus, until the program’s own building is completed both on campus and in Taipei.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200512005343/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
FDA Issues Modified Risk Tobacco Product Orders for 20 ZYN Nicotine Pouch Products30.6.2026 18:19:00 CEST | Press release
FDA’s decision makes ZYN the first nicotine pouch product to receive MRTP orders authorizing reduced-risk claims versus cigarettes Philip Morris International Inc. (PMI) (NYSE: PM) today announced that the U.S. Food and Drug Administration (FDA) issued Modified Risk Tobacco Product (MRTP) orders for 20 variants of ZYN nicotine pouch products. These are the first MRTP orders granted for nicotine pouches, allowing PMI U.S. to market the following claim for the authorized ZYN products: “Using ZYN instead of cigarettes puts you at a lower risk of mouth cancer, heart disease, lung cancer, stroke, emphysema, and chronic bronchitis.” “FDA’s decision is an important moment for the more than 45 million legal-age nicotine consumers in America,” saidStacey Kennedy, PMI U.S. CEO. “Today’s news ensures these adultshave access to accurate, science-based information, including FDA-authorized evidence that switching from cigarettes to ZYN reduces the risk of smoking-related diseases like heart disease
Caidya Announces Strategic Combination with Simbec-Orion Bridging Early Scientific Insight and Global Clinical Execution30.6.2026 17:00:00 CEST | Press release
Caidya today announced a strategic combination with Simbec-Orion designed to close the divide between early scientific insight and global clinical execution. The combination of Caidya and Simbec-Orion creates a differentiated specialty clinical CRO platform that enables programs to scale, maintaining focus, speed, and accountability. The strategic combination brings together complementary strengths to create a more complete development partner for innovative biopharma companies. With established operations across Europe, the Americas, APAC, and China, the combined organization provides meaningful expertise and execution capabilities in the regions that matter most. Simbec-Orion brings early-phase clinical pharmacology capabilities alongside deep therapeutic expertise for later stage complex oncology and rare disease trials, helping sponsors shape critical decisions early in the development lifecycle. Together, the organizations strengthen their ability to support complex, cross-border
Archer® Proves Purpose-Built AI Beats General-Purpose LLMs on Regulatory Change Management: 95% Verified Accuracy, 80x Faster, 92% Lower Cost30.6.2026 16:13:00 CEST | Press release
In a head-to-head benchmark, a leading general-purpose LLM was confidently wrong 35% of the time on regulatory dates. Archer Evolv™ shipped zero errors. For enterprises deploying AI in compliance, a wrong date is a missed deadline. The more dangerous failure is a wrong answer the model returns with high confidence, one that flows silently into a compliance calendar and is only discovered after the window has passed. Archer® today released results showing purpose-built AI beats a general-purpose large language model (LLM) on regulatory work, and it’s not close. This head-to-head test compared Archer’s purpose-built, vertical-specific AI and proprietary data sets against a leading general-purpose LLM, on a core compliance task: determining the publication, effective and comment-close dates of regulatory documents across six jurisdictions. General-purpose models are a genuine breakthrough, and this is no referendum on their quality. The question Archer set out to answer is narrower and mo
Altasciences Supports Key Development Milestone for Steel Therapeutics’ Lead Therapeutic Candidate, Fizurex™30.6.2026 16:08:00 CEST | Press release
Altasciences, a leading drug development organization, today announced a significant milestone in the development of Steel Therapeutics, Inc.’s pivotal toxicology study for its lead product candidate, Fizurex™, for the treatment of anal fissures. The successful completion of the study plays a significant role in the advancement of Fizurex™ toward first-in-human trials. The GLP-compliant study demonstrated a favorable safety profile, which has advanced Steel Therapeutics' plans to submit an Investigational New Drug (IND) application for Fizurex™ to the FDA in Q3 2026. Fizurex™, a patent-pending, single-use topical wipe, was designed to provide a standardized, accessible treatment option for a painful and often undertreated medical condition. The product builds on years of use through compounding pharmacy prescriptions and is now advancing toward clinical development and regulatory review. "We are proud to have supported Steel Therapeutics with the generation of the high-quality safety d
Interactive Brokers Expands Access to Korean Equities with Launch of Nextrade ATS30.6.2026 16:00:00 CEST | Press release
IB SmartRouting℠ Routes Orders to the Best Available Price Between KRX and Nextrade Interactive Brokers (Nasdaq: IBKR), an automated global broker, today announced the launch of select Korean equities through Nextrade, South Korea's first Alternative Trading System (ATS). The addition of Nextrade builds on Interactive Brokers' earlier launch of the Korea Exchange (KRX), through which it became the first major US-based broker to provide global investors with direct access to Korean equities. Clients trading on Nextrade benefit from significantly extended trading hours and access to additional liquidity. Interactive Brokers has enabled IB SmartRouting℠ across both the Korea Exchange (KRX) and Nextrade, automatically routing orders to the venue offering the best price. This helps clients achieve best execution while providing greater flexibility and more opportunities to participate in one of Asia's most dynamic equity markets. Korea's equity market ranks among the top global exchanges by
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
